KetaMind Health Research
Why Choose KetaMine Health?
- Real-world effectiveness of maintenance ketamine infusions for treatment-resistant depression in major depressive disorder and bipolar disorder (Sipan et al., 2025)
- Clinical Outcomes of Intravenous Ketamine Treatment for Depression in the VA Health System (Dara et al., 2024)
- Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression (Amit et al., 2023)
- Ketamine for the Treatment of Major Depression (Stevan et al., 2023)
- The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis (Tuuli et al., 2023)
- Neurocognitive effects of repeated ketamine infusion treatments in patients with treatment-resistant depression: a retrospective chart review (Danika et al., 2022)
- A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings (Alison et al., 2022)
- A qualitative study of patients' experience of ketamine treatment for depression: The ‘Ketamine and me’ projec (Chris et al., 2021)
- A qualitative study of patients' experience of ketamine treatment for depression: The ‘Ketamine and me’ projec (Chris et al., 2021)
- Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: A retrospective chart review (Hitoshi et al., 2020)
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression (Carlos et al., 2006)
- Antidepressant effects of ketamine in depressed patients (RM et al., 2000)